-
公开(公告)号：US20210113466A1
公开(公告)日：2021-04-22
申请号：US16494568
申请日：2018-03-16
发明人： Marsha A. Moses , Peng Guo , Jiang Yang , Debra Auguste
摘要： Some aspects of the present disclosure provide nanoparticles comprising a non-cationic liposome with ligands conjugated to its surface and a hydrogel encapsulated in the liposome. In some embodiments, the nanoparticle is used as a delivery system to deliver an agent (e.g., a therapeutic agent or a genome-editing agents) to a cell (e.g., a diseased cell such as a cancer cell). The ligands on the surface of the cationic liposome targets the liposome to cells that express proteins targeted by the ligands on their surface. Methods of treating diseases and disorders, as well as methods of genome-editing are also provided.
-
公开(公告)号：US20140242616A1
公开(公告)日：2014-08-28
申请号：US14030868
申请日：2013-09-18
发明人： Marsha A. Moses , Jiang Yang
IPC分类号： G01N33/574
CPC分类号： G01N33/57496 , G01N33/57415 , G01N33/57449 , G01N33/57488 , G01N2333/47
摘要： Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer.
摘要翻译： 未复合的嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）以增加的水平存在于具有非典型导管增生（ADH）的个体中，这是未来乳腺癌发展的主要风险因素; 卵巢癌患者; 以及具有乳腺癌的个体，既有创伤性又有侵袭性。 因此，本发明涉及测量尿液中未复合的NGAL水平作为主要屏幕，以确定个体是否处于发展的风险中，或已经发展为癌症，例如包括乳腺癌和卵巢癌在内的上皮癌症。
-
公开(公告)号：US11260132B2
公开(公告)日：2022-03-01
申请号：US16494551
申请日：2018-03-16
发明人： Marsha A. Moses , Peng Guo , Jiang Yang , Debra Auguste , Daxing Liu
摘要： The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).
-
4.发明申请公开(公告)号：US20200308620A1
公开(公告)日：2020-10-01
申请号：US16759713
申请日：2018-10-26
发明人： Marsha A. Moses , Peng Guo , Debra Auguste , Jiang Yang , Daxing Liu
摘要： Provided herein are methods of using atomic force microscopy (AFM) to measure the adhesion force between a cell surface target and a ligand (e.g., an antibody) that binds to the cell surface target. Such adhesion force serves as an in vitro metric for predicting the in vivo tumor recognition and/or anti-tumor efficacy of antibody-directed nanomedicine.
-
公开(公告)号：US20200085972A1
公开(公告)日：2020-03-19
申请号：US16494551
申请日：2018-03-16
发明人： Marsha A. Moses , Peng Guo , Jiang Yang , Debra Auguste , Daxing Liu
摘要： The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).
-
公开(公告)号：US20180238896A1
公开(公告)日：2018-08-23
申请号：US15712692
申请日：2017-09-22
发明人： Marsha A. Moses , Jiang Yang
IPC分类号： G01N33/574
CPC分类号： G01N33/57496 , G01N33/57415 , G01N33/57449 , G01N33/57488 , G01N2333/47
摘要： Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer.
-
公开(公告)号：US20170082631A1
公开(公告)日：2017-03-23
申请号：US15135460
申请日：2016-04-21
发明人： Marsha A. Moses , Jiang Yang
IPC分类号： G01N33/574
CPC分类号： G01N33/57496 , G01N33/57415 , G01N33/57449 , G01N33/57488 , G01N2333/47
摘要： Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.02 秒)
